Today, Juno Therapeutics Inc (JUNO) Lowered by SunTrust Banks Inc. to “Hold”

Today, Juno Therapeutics Inc (JUNO) Lowered by SunTrust Banks Inc. to “Hold”

Juno Therapeutics Inc (NASDAQ:JUNO) was downgraded by research analysts at SunTrust Banks Inc. from a “buy” rating to a “hold” rating in a research note issued to investors on Friday. They presently have a $25.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $48.00. SunTrust Banks Inc.’s price target would indicate a potential upside of 10.82% from the stock’s current price.

Other analysts also recently issued research reports about the stock. FBR & Co reiterated an “outperform” rating and issued a $61.00 price target on shares of Juno Therapeutics in a research report on Saturday, October 15th. BTIG Research upgraded shares of Juno Therapeutics from a “sell” rating to a “neutral” rating in a research report on Thursday, November 3rd. Zacks Investment Research upgraded shares of Juno Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, September 6th. Vetr upgraded shares of Juno Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 23rd. Finally, Maxim Group cut their price objective on shares of Juno Therapeutics from $50.00 to $34.00 and set a “buy” rating for the company in a research report on Wednesday. Six research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $41.47.

Juno Therapeutics (NASDAQ:JUNO) opened at 22.56 on Friday. The firm’s market capitalization is $2.31 billion. The company’s 50-day moving average is $27.75 and its 200-day moving average is $33.02. Juno Therapeutics has a 52-week low of $19.41 and a 52-week high of $57.82.

Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.52) by $0.05. The company had revenue of $20.80 million for the quarter, compared to analysts’ expectations of $10.98 million. During the same period last year, the business posted ($0.26) EPS. Juno Therapeutics’s revenue was up 1200.0% compared to the same quarter last year. Equities analysts predict that Juno Therapeutics will post ($2.54) earnings per share for the current year.

In related news, CEO Hans Edgar Bishop sold 44,000 shares of the stock in a transaction dated Tuesday, September 27th. The shares were sold at an average price of $33.00, for a total value of $1,452,000.00. Following the sale, the chief executive officer now directly owns 2,490,859 shares of the company’s stock, valued at approximately $82,198,347. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Robert Azelby sold 12,921 shares of the stock in a transaction dated Thursday, November 10th. The shares were sold at an average price of $24.14, for a total transaction of $311,912.94. Following the completion of the sale, the executive vice president now directly owns 48,640 shares in the company, valued at $1,174,169.60. The disclosure for this sale can be found here.

Large investors have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD boosted its stake in shares of Juno Therapeutics by 0.4% in the third quarter. Price T Rowe Associates Inc. MD now owns 23,698 shares of the biopharmaceutical company’s stock worth $711,000 after buying an additional 98 shares during the last quarter. Boyer & Corporon Wealth Management LLC boosted its stake in Juno Therapeutics by 0.9% in the second quarter. Boyer & Corporon Wealth Management LLC now owns 12,579 shares of the biopharmaceutical company’s stock valued at $484,000 after buying an additional 115 shares in the last quarter. Profund Advisors LLC boosted its stake in Juno Therapeutics by 0.4% in the second quarter. Profund Advisors LLC now owns 39,877 shares of the biopharmaceutical company’s stock valued at $1,533,000 after buying an additional 148 shares in the last quarter. Legal & General Group Plc boosted its stake in Juno Therapeutics by 5.9% in the second quarter. Legal & General Group Plc now owns 5,470 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 306 shares in the last quarter. Finally, BlackRock Investment Management LLC boosted its stake in Juno Therapeutics by 1.3% in the third quarter. BlackRock Investment Management LLC now owns 25,635 shares of the biopharmaceutical company’s stock valued at $769,000 after buying an additional 320 shares in the last quarter.

About Juno Therapeutics

Related posts

Leave a Comment